文献速递白血病

BRD4降解阻断Ph+慢性髓性白血病中MYC表达及多种干细胞耐药形式

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia.
PubMed 文献 · Am J Hematol · 2022-07-18

研究鉴定表观遗传阅读器BRD4及其下游效应分子MYC为CML细胞的生长调节因子和治疗靶点,BRD4降解剂dBET6可阻断所有受试患者原代CML细胞增殖和/或存活,包括急变期和携带T315I变异的CML细胞,并克服多种耐药形式。

要点

  • BRD4和MYC在原代CML细胞、CD34+/CD38-白血病干细胞及CML细胞系中表达。
  • BRD4降解剂dBET6阻断所有受试患者原代CML细胞增殖和/或存活,包括急变期和T315I变异。
  • dBET6在共培养系统中克服成骨细胞诱导的CML干细胞TKI耐药,并阻断干扰素-γ诱导的PD-L1上调。

核心结论

  • 通过BET降解靶向BRD4和MYC可使CML细胞对BCR::ABL1 TKI敏感,是克服CML白血病干细胞多种耐药形式的有效方法。

研究设计与样本

  • 研究使用原代CML细胞、CD34+/CD38-白血病干细胞、CML细胞系KU812、K562、KCL22和KCL22T315I,以及共培养系统和NSG小鼠移植模型。

主要发现

  • BRD4和MYC表达于原代CML细胞、CD34+/CD38-白血病干细胞及CML细胞系KU812、K562、KCL22和KCL22T315I。
  • JQ1抑制多数慢性期CML患者的KU812细胞和原代白血病细胞增殖,但在急变期CML中效果较差。
  • dBET6阻断所有受试患者原代CML细胞增殖和/或存活,包括急变期CML和携带T315I变异的CML细胞。
  • dBET6阻断MYC表达,并与BCR::ABL1 TKI协同抑制JQ1耐药细胞系K562的增殖。
  • BRD4降解在共培养系统中克服成骨细胞诱导的CML白血病干细胞TKI耐药,并阻断干扰素-γ诱导的白血病干细胞PD-L1上调。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream-effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34+ /CD38- leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22T315I . The BRD4-targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1-resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast-induced TKI resistance of CML LSC in a co-culture system and to block interferon-gamma-induced upregulation of the checkpoint antigen PD-L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Peter B, Eisenwort G, Sadovnik I, et al. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia. Am J Hematol. 2022. PMID: 35794848. doi:10.1002/ajh.26650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。